Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Guest Speaker Dr. Sarwish Rafiq from the Department of Hematology and Medical Oncology at Emory University School of Medicine will discuss current roadblocks in CAR T cell therapy and how researchers are engineering strategies to overcome these challenges. We will explore optimization of the efficacy and efficiency of CARs along with how to make them safer.
About the Speaker
Sarwish Rafiq, PhD, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Rafiq earned her PhD in Immunology/Cancer Biology from The Ohio State University in Columbus, Ohio. She completed her post-doctoral training in cellular immunotherapy at Memorial Sloan Kettering Cancer Center in New York, New York. The overall goal of Dr. Rafiq’s research is to use mechanistic insight of immune effector cell function and interaction with cancer cells in the tumor microenvironment to inform the development and translation of novel engineered cellular immunotherapies. In particular, her work focuses on the genetic engineering of synthetic receptors known as Chimeric Antigen Receptors (CAR). As a translational cancer researcher, Dr. Rafiq’s studies aim to engineer novel CARs to target both solid and hematological malignancies as well as deliver immune-modulating or toxic agents locally to the tumor microenvironment.
*Moxi GO II discussed is for Research Use Only.